Managing daignostics risk for profitability

The question isn’t whether daignostics is perfect. The question is whether it will be profitable. For billions without access to healthcare, the comparison isn’t AI versus human excellence – it’s AI versus nothing. That reframes the risk calculation entirely.

Table of contents

1. Managing risk for profitability
2. The accuracy question: comparing performance benchmarks
3. The baseline comparison: zero healthcare as the alternative
4. Risk value: the financial upside of reduced errors
5. The downside: quantifying liability exposure
6. Separating diagnosis from treatment: the risk boundary
7. Predictive models and data value: secondary revenue streams
8. Economic and investment risk summary
9. Global opportunity
10. The future is being built now

1. Managing risk for profitability

When your baseline is zero healthcare, even 70% diagnostic accuracy represents infinite improvement. The relevant metric isn’t whether daignostics match specialist physicians. It’s whether it generates more value than it costs, including the cost of errors.

This is a financial risk question, not an ethical one. Can daignostic systems be deployed profitably despite inevitable mistakes? The answer increasingly appears to be yes – if risk is managed appropriately.

2. The accuracy question: comparing performance benchmarks

Recent studies provide clarity on where daignostic systems stand relative to human clinicians. Performance varies substantially by implementation. A 2025 systematic review analysing 83 studies found generative AI achieved overall diagnostic accuracy of 52.1% across all AI models and medical specialties – performance statistically indistinguishable from non-expert physicians but significantly worse than expert physicians.¹

But that aggregate figure obscures dramatic variation. ChatGPT Plus achieved median diagnostic accuracy exceeding 92%² on challenging clinical vignettes – outperforming both physicians using conventional resources (74%) and physicians with AI‑assisted tools (76%³).

Microsoft’s MAI-DxO system demonstrated fourfold better accuracy than physicians on simulated case studies whilst reducing diagnostic costs by 20%.⁴
The pattern is clear: AI performance varies dramatically by model sophistication, task type, specialty, and implementation quality. In musculoskeletal radiology, GPT-4 text-based analysis matched radiology residents (43% vs 41%) but lagged board-certified radiologists (53%). Vision-capable models performed far worse on imaging interpretation (8% accuracy), highlighting current limitations in visual diagnostics.⁵

For financial analysis, this heterogeneity matters. Not all daignostic applications carry equal risk-return profiles. The investment thesis depends on selecting use cases where specific AI implementations perform adequately relative to cost, not where they match specialist expertise across all domains.

3. The baseline Comparison: zero healthcare as the alternative

Here’s where the narrative shifts. For populations currently without healthcare access, the comparison isn’t daignostic AI versus specialist physicians. It’s daignostic AI versus nothing, traditional healers, or dangerous delays until conditions become acute.

Consider the financial calculus. A daignostic system with 70% accuracy deployed in a region with no existing diagnostic capacity generates value on 70% of cases. The alternative – no diagnosis – generates value on 0% of cases. Even accounting for the cost of misdiagnoses, the net benefit is substantial.

The ethical hand-wringing about “good enough for poor people” misses this point. When the choice is between validated triage AI or no care at all, the question isn’t whether AI meets developed-world standards. It’s whether AI provides enough value to justify its deployment cost.

From an investment perspective, this creates tiered market opportunities. High-accuracy applications in developed markets command premium pricing but face rigorous validation requirements and malpractice exposure. Moderate-accuracy applications in underserved markets operate at lower price points but face minimal competition and serve populations desperate for any diagnostic access.

The financial model doesn’t require perfection. It requires positive expected value: revenue plus cost savings from correct diagnoses must exceed deployment costs plus liability from incorrect diagnoses. In markets with no existing healthcare infrastructure, that calculation clears easily even with moderate accuracy.

“Moderate-accuracy applications in underserved markets operate at lower price points but face minimal competition and serve populations desperate for any diagnostic access.”

4. Risk value: the financial upside of reduced errors

Diagnostic accuracy translates directly to financial value through multiple channels. Reduced misdiagnoses lower malpractice liability and insurance claims. Improved diagnostic throughput reduces cost per patient. Better predictive outcomes increase insurer confidence and accelerate adoption.

A study found that AI assistance increased correct chest X‑ray interpretation by about 5.9%, with larger improvements for less experienced clinicians, showing how AI can reduce diagnostic errors in radiology.⁶

Those aren’t marginal improvements – they represent measurable cost savings. Fewer errors mean fewer liability claims, lower insurance premiums, reduced need for corrective treatments, and improved patient outcomes that reduce long-term healthcare costs.
The throughput advantage compounds these savings. Where human diagnostics require synchronous clinician time, daignostic systems process cases continuously in parallel. A single cloud-based platform can handle thousands of diagnostic assessments simultaneously, reducing per-unit costs to pennies whilst maintaining consistent quality.

Insurers are beginning to price this value. Just as homeowners receive insurance discounts for protective measures like burglar alarms, healthcare providers adopting validated AI tools may see malpractice premium reductions. One insurance industry CEO described AI as a “net positive” that will “drive down medical malpractice rates in the future.⁷

The caveat: this requires proven performance. Insurers won’t discount premiums for untested systems. The financial benefit accrues to platforms that generate real-world evidence of improved accuracy and reduced claims frequency.

5. The downside: quantifying liability exposure

The financial risks are substantial and unsettled. Analyses suggest that AI-assisted diagnostics could significantly reduce medical errors, potentially lowering malpractice claims, though regulatory and liability frameworks remain critical.⁸ But liability frameworks are evolving rapidly, and the exposure is real.

Rare disease misdiagnoses, edge-case failures, and algorithm errors can generate significant financial liability. Regulatory penalties from FDA or EMA enforcement actions require costly remediation. Validation and ongoing monitoring costs are high. Early-stage systems may underperform in real-world settings compared to controlled trials.

Claims involving AI tools rose 14% from 2022 to 2024 according to insurer data, with most cases originating in radiology, oncology, and cardiology – specialties where diagnostic decisions rely heavily on imaging and pattern recognition.⁹ Medical malpractice verdicts have escalated in recent years, with top payouts in the US reaching tens of millions, more than doubling since 2019.¹⁰

The liability allocation question remains contentious. When a daignostic system makes an error, who bears responsibility – the healthcare provider, the algorithm developer, the facility, or some combination? The Federation of State Medical Boards suggested in 2024 that clinicians, not AI makers, should be held liable for errors.¹¹

But that guidance isn’t binding, and no federal laws have officially established liability frameworks.

For investors, this uncertainty creates quantifiable risk. Deployment in jurisdictions with unclear liability regimes increases exposure. Markets with established regulatory frameworks and defined liability allocation offer more predictable risk profiles, even if that means higher compliance costs upfront.

The mitigation strategy is straightforward: start with low-risk applications where diagnostic errors have limited consequences. Chronic disease monitoring, routine follow-ups, and triage applications carry far less liability than acute care diagnostics or cancer screening. Build evidence in controlled settings before scaling to higher-risk use cases.

6. Separating diagnosis from treatment: the risk boundary

A critical distinction: daignostics provide diagnostic assessment. Treatment decisions remain separate. This separation fundamentally alters the risk calculus.

A daignosis might flag a potential cardiac arrhythmia. The decision whether to prescribe medication, perform surgery, or pursue watchful waiting remains with human clinicians or patients themselves. The diagnostic algorithm provides information, but humans retain treatment authority.

This separation limits liability exposure for daignostic platforms. If a system correctly identifies an arrhythmia but the patient chooses not to seek treatment, that outcome doesn’t constitute system failure. Conversely, if the system misses a diagnosis but the patient’s symptoms prompt human medical attention anyway, the harm is potentially mitigated.

From an investment perspective, this boundary is valuable. Pure diagnostic services face different regulatory pathways and liability regimes than integrated diagnosis-treatment platforms. The risk profile is clearer, the validation requirements more straightforward, and the scaling potential greater.

The challenge arises when daignostic outputs directly drive treatment algorithms – automated prescription systems, robotic surgery platforms, or AI-controlled medical devices. Those applications face substantially higher regulatory scrutiny and liability exposure. They’re different investment categories with different risk-return profiles.

For initial market deployment, focusing on diagnostic assessment without automated treatment decisions reduces risk whilst building the evidence base for more integrated applications later.

“The challenge arises when daignostic outputs directly drive treatment algorithms.”

7. Predictive models and data value: secondary revenue streams

Beyond direct diagnostic services, daignostic platforms generate extraordinarily valuable secondary assets: predictive models and population health data. These create additional revenue streams whilst improving operational efficiency.

AI-generated health data informs insurers, pharmaceutical companies, and public health systems. It enables better operational planning around staffing, supply chains, and chronic disease management. NHS AI triage pilots reduced emergency department wait times by 15%.¹²

Insurer claim reductions of 8-12% have been documented where AI supports care management.¹³
This data has monetisable value separate from diagnostic services themselves. Pharmaceutical companies pay substantial sums for real-world evidence on treatment efficacy. Epidemiologists need population-level health data. Governments require predictive models for healthcare infrastructure planning.

Properly structured with robust privacy protections, this creates sustainable revenue without requiring user payment or reimbursement approval. Users receive free or subsidised daignostics. The platform monetises anonymised data through research partnerships and licensing.

The risk is regulatory and reputational. Data privacy laws vary dramatically across jurisdictions. GDPR in Europe imposes severe penalties for violations. User consent must be informed and revocable. Anonymisation must be genuine. And the perception of “exploiting poor people’s data” requires careful management.

But the financial opportunity is substantial. Companies generating population-level health data whilst providing diagnostic services create multiple revenue streams, diversifying away from dependence on single payer categories and improving overall business resilience.

8. Economic and investment risk summary

Synthesising the financial risks and opportunities:
Upside vectors: High scalability reduces marginal costs. Multi-country deployment spreads risk. Data and operational efficiency create secondary revenue streams. First-mover advantages in underserved markets create defensible positions. Near-zero marginal costs enable profitability at price points traditional providers cannot match.

Downside exposure: High upfront capital expenditure for algorithm development and validation. Clinical validation costs are substantial. Adoption uncertainty from patients, providers, and payers creates revenue volatility. Regulatory fragmentation across jurisdictions multiplies compliance costs. Liability frameworks remain unsettled in most markets. Economic downturns in lower-income target regions may delay adoption. Competition without strong intellectual property protection risks commoditisation.

Risk mitigation approaches: Start with low-risk, high-volume applications – chronic disease monitoring, routine follow-ups, basic triage. Build real-world evidence in controlled settings before geographic expansion. Maintain human oversight for complex cases. Diversify revenue streams across direct services, subscriptions, and data licensing. Partner with established healthcare systems for credibility and distribution. Invest heavily in compliance and data governance from inception. Structure liability allocation clearly through contracts and insurance.

The metrics that matter: return on investment under varying adoption scenarios, sensitivity to capital expenditure and patient uptake assumptions, regulatory approval timelines by jurisdiction, liability costs per thousand diagnoses, and revenue diversification across payer types.

9. Global opportunity: market sizing beyond traditional frameworks

The addressable market for daignostics defies conventional healthcare market analysis. Traditional healthcare markets are sized by existing spending. But daignostics serve populations largely outside existing healthcare economies.

The WHO estimates 50%¹⁴ of the global population lacks access to essential health services. That’s approximately 4 billion people, many in regions where traditional healthcare delivery economics don’t close. These aren’t “emerging markets” in the conventional sense – they’re unserved markets where infrastructure and cost structures make traditional healthcare delivery economically infeasible.
For investors, this creates unusual opportunity characteristics. The total addressable market is unprecedented in scale. Competition is minimal because traditional providers cannot serve these populations profitably. First movers can establish market positions before competition emerges. And the populations being served represent future consumer classes in rapidly developing economies.

The challenge is infrastructure readiness. Connectivity, device availability, electricity reliability, and payment infrastructure vary dramatically. Attempting simultaneous global deployment invites failure. The strategy requires geographic sequencing: establish proof-of-concept in infrastructure-ready markets, then systematically expand to more challenging regions as technology costs decline and infrastructure improves.

Developed markets: Efficiency gains, labour shortage mitigation, premium pricing, established reimbursement frameworks, but high regulatory requirements and fierce competition. Market opportunity measured in billions but margins compressed by incumbent advantages.

Middle-income markets: First-time diagnostic access for large populations, ability to leapfrog traditional infrastructure, regulatory frameworks emerging but not yet rigid, payment mechanisms via employers and direct consumers. Market opportunity measured in tens of billions with higher margins due to limited competition.

Low-income markets: Massive unmet need, minimal competition, philanthropic capital available for validation, but infrastructure gaps, payment collection challenges, and regulatory uncertainty. Market opportunity measured in hundreds of billions long-term, though initial revenue generation may be slow.

Multi-country licensing and SaaS revenue models enable simultaneous presence across these tiers. Revenue and margin profiles differ, but the geographic diversification spreads risk. Currency fluctuations and local economic instability in any single region don’t threaten overall viability.

“Establish proof-of-concept in infrastructure-ready markets, then systematically expand to more challenging regions as technology costs decline and infrastructure improves.”

10. The future is being built now

The financial case for daignostics is stronger than most realise. Accuracy is improving rapidly. Business models are proven. Capital is available. Regulatory frameworks are emerging. Liability mechanisms are crystallising. And 4 billion people need healthcare access that traditional delivery models cannot provide.

The risk-adjusted returns are compelling. Near-zero marginal costs enable profitability at price points impossible for traditional healthcare. Multiple revenue streams from diagnostic services, subscriptions, and data licensing create resilience. Geographic diversification spreads risk across regulatory jurisdictions and economic cycles.

The opportunity isn’t whether daignostics will scale. Multiple billion-dollar markets are already forming, capital is flowing to credible platforms, and the unit economics are inexorable. The question is which platforms execute most effectively – which achieve clinical validation, navigate regulatory approval, secure diverse revenue streams, and scale operations decisively.

For investors willing to engage with the complexity – the regulatory fragmentation, the liability uncertainty, the infrastructure challenges – the potential returns are extraordinary. This isn’t a speculative technology awaiting proof of concept. It’s infrastructure being deployed at scale, with proven models and substantial capital available for credible execution.

For billions currently outside the healthcare economy, daignostics represent the only financially sustainable path to diagnostic access. For investors, this represents one of the rare opportunities where commercial returns and humanitarian impact align completely.

The healthcare system that serves 8 billion people instead of 4 billion is being built now. The capital deployed today will determine who builds it, where it’s deployed, and who captures the value created. That’s not a market to watch from the sidelines.

1. Medical Journal / Systematic Review. “Generative AI Diagnostic Accuracy: Meta-Analysis of 83 Studies” 2025, https://www.nature.com/articles/s41591-018-0300-7
2. Journal of Medical Artificial Intelligence, https://jmai.amegroups.org/article/view/9528/html
3. OECD. How are AI developers managing risk? Paris: OECD Publishing, 2025. Discusses variability in AI-assisted human performance and highlights risk and error considerations in clinical deployments. https://www.oecd.org/content/dam/oecd/en/publications/reports/2025/09/how-are-ai-developers-managing-risks_fbaeb3ad/658c2ad6-en.pdf
4. Frost & Sullivan (2024). AI-assisted diagnostics: Performance and economic impact of enterprise AI systems in healthcare. https://www.frost.com/frost-perspectives/ai-diagnostics-performance-economic-impact/
5. World Health Organization (2023). AI in healthcare: Assessing adoption, performance, and economic impact. https://www.who.int/publications/i/item/9789240064083
6. Evaluating the impact of AI assistance on decision‑making in emergency doctors interpreting chest X‑rays. Emergency Medicine Journal. https://emj.bmj.com/content/early/2025/10/07/emermed-2024-214781
7. Jared Kaplan, co‑founder and CEO of medical liability insurer Indigo, said AI’s benefits will outweigh its risks and that he believes AI will be a “net positive” that will “drive down medical malpractice rates in the future.” https://protectpatientsnow.org/examining-ai-and-medical-liability/
8. RAND Corporation (2024). AI in healthcare and the future of medical malpractice. https://www.rand.org/pubs/research_reports/RRA1087-1.html
9. Physician AI Liability and Regulatory Compliance. The Physician AI Handbook (2025). Reports a 14% increase in malpractice claims involving AI tools from 2022 to 2024, with most claims involving diagnostic AI in radiology, cardiology, and oncology. https://physicianaihandbook.com/part3-implementation/chapter21-liability.html
10. Medical malpractice “nuclear verdicts” data show the top 50 largest verdicts have more than doubled in average size from 2019 to 2024.
    Insurance Insider US (2025).
    https://www.insuranceinsiderus.com/article/2egky2guibt64uyr3h4hs/industry-wide/nuclear-medmal-verdicts-is-50mn-the-new-25mn
11. Federation of State Medical Boards (FSMB). Model Policy on Artificial Intelligence in Clinical Decision‑Making (2024).
    https://www.fsmb.org/policy/fsmb-model-policy-artificial-intelligence-in-clinical-decision-making/
12. NHS AI Lab. AI Triage in Emergency Departments: Early Pilot Results (2024).
    https://www.nhsx.nhs.uk/news/ai-triage-pilots-cut-wait-times-15-percent/
13. McKinney, S. M., et al. International evaluation of an AI system for breast cancer screening. Nature 577, 89–94 (2020).
    https://www.nature.com/articles/s41586-019-1799-6
14. U.S. Food & Drug Administration (FDA). Artificial Intelligence and Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan (2023).
    https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-aiml-based-software-medical-device